All articles tagged with #sildenafil
A Weizmann Institute study (with U.S. data) suggests sildenafil (Viagra) can limit cancer’s ability to metastasize by disrupting cholesterol use inside cells via PDE5 inhibition and higher cGMP; researchers propose combining Viagra-related drugs with statins to slow spread. However, findings are observational and based on mouse data, so not yet proven in humans.
Sildenafil (Viagra) appears to disrupt cholesterol trafficking in cancer cells, limiting their ability to spread in mouse models of breast, lung, and colon cancer, while a retrospective analysis of health records from over 40,000 male cancer patients linked combined sildenafil and statin use to about a 31% lower five-year mortality versus neither drug. The results are observational and require clinical trials to confirm causality.
A Weizmann Institute study suggests sildenafil (Viagra’s active ingredient) may slow cancer metastasis by disrupting how cancer cells use cholesterol, potentially reducing the spread to distant tumors. The work combines human data, cell and mouse experiments, and suggests that pairing PDE5 inhibitors with statins could help limit tumor spread, but the human evidence is observational and does not prove causation; more research is needed before clinical application.
New research suggests sildenafil (Viagra) may slow cancer metastasis by disrupting cholesterol transport inside cancer cells, effectively starving tumors of a key resource. The findings—spanning mouse models, patient-derived cancer cells, and large health records—also point to better survival when sildenafil is used with statins, highlighting the influence of a patient’s metabolic state on cancer progression.
A study led by the Weizmann Institute of Science suggests sildenafil (Viagra) may prevent cancer cells from spreading by causing cholesterol to accumulate in recycling compartments, depriving tumors of cholesterol needed for invasion; while promising, clinical trials are needed to confirm it can reduce metastasis in patients.
Medicines often find new uses after their initial purpose; sildenafil, finasteride, and minoxidil were repurposed from heart, prostate, and blood-pressure indications to treat erectile dysfunction and hair loss, illustrating how serendipity and careful observation drive medical progress and highlighting the benefits and caveats of drug repurposing in men's health.
A Delphi-consensus by 21 experts named sildenafil (Viagra), Zostavax, and riluzole as the leading repurposed drug candidates for Alzheimer's prevention and treatment, highlighting their potential mechanisms and the need for rigorous clinical trials before any approved use.
A panel of researchers identified three approved medicines with potential to prevent or treat Alzheimer’s disease: the shingles vaccine (Zostavax), sildenafil (Viagra), and riluzole. These drugs target relevant Alzheimer’s mechanisms, have safety profiles suitable for older adults, and show promising results in cell/animal studies, prompting calls for robust clinical trials to determine true benefit and establish whether they can slow or prevent dementia.
A Chinese study suggests that sildenafil, commonly known as Viagra, may have potential in cancer treatment by enhancing immune cells that fight tumors, offering a new avenue for tumor immunotherapy.
A study suggests that Viagra (sildenafil) may help increase bone cell production and prevent bone loss, potentially offering a new treatment for osteoporosis in older adults, with additional benefits like reducing dementia risk.
New research suggests that sildenafil, the active ingredient in Viagra, may help reduce the risk of developing Alzheimer's disease. Studies have shown a potential link between sildenafil use and a decreased likelihood of Alzheimer's diagnosis, with some evidence indicating its ability to promote neuron growth and reduce the accumulation of toxic proteins. While further clinical trials are needed to confirm its effectiveness, researchers believe these findings warrant larger-scale investigations into sildenafil as a potential treatment for Alzheimer's.
A new observational study suggests that taking sildenafil, the active ingredient in Viagra, may lower the risk of developing Alzheimer's disease. However, unanswered questions remain, and more research is needed to understand the potential link and physiological mechanism. The study included an analysis of insurance claims data from over 2 million patients with pulmonary arterial hypertension, revealing a lower risk of Alzheimer's among those taking sildenafil. Lab experiments also showed potential benefits, but experts emphasize the need for well-designed clinical trials to provide a robust evidence base for considering sildenafil as a potential treatment for Alzheimer's disease.
A new study suggests that sildenafil, the main ingredient in Viagra, may reduce the risk of developing Alzheimer's disease. The research observed a 30% to 54% reduction in Alzheimer's incidence among people taking sildenafil for erectile dysfunction or pulmonary arterial hypertension. Lab research also found that sildenafil lowered levels of neurotoxic tau proteins and promoted improved brain function. However, experts caution that further exploration and clinical trials are needed to determine if sildenafil can effectively treat Alzheimer's, and warn against using such medications without consulting a physician.
A new study suggests that sildenafil (Viagra) may reduce the prevalence of Alzheimer's disease (AD) by 30%-54%, based on real-world patient data and mechanistic studies. The research, led by Feixiong Cheng, PhD, director of the Cleveland Clinic Genome Center, indicates that sildenafil could potentially be repurposed as a treatment for AD, supported by its ability to decrease neurotoxic protein levels in brain cells. The findings provide evidence for further clinical trials to examine the effectiveness of sildenafil in patients with Alzheimer's disease.
A new study led by the Cleveland Clinic suggests that sildenafil, the main component of Viagra, shows potential as a treatment for Alzheimer's disease. The research, which integrates computational models, insurance claims data, and laboratory observations, indicates a 30-54% reduction in Alzheimer's diagnoses among sildenafil users and decreased levels of neurotoxic proteins in brain cells. This interdisciplinary approach highlights the benefits of drug repurposing and offers a promising avenue for new Alzheimer's therapies, with implications for future clinical trials to explore sildenafil's effectiveness in patients with Alzheimer's disease.